Translation errors, impaired folding or environmental stressors (e.g. infection) can all lead to an increase in the presence of misfolded proteins. These activate cellular responses to their removal, including intracellular protein degradation activities. Protein ubiquitylation is involved in two major degradation pathways, the ubiquitin-proteasome system and selective autophagy. In humans, the ubiquitin-like modifier-activating enzyme 1 (UBA1) is the primary E1 enzyme in the ubiquitin conjugation cascade. Viruses have evolved to exploit protein degradation pathways to complete their infection cycles. Zika virus (ZIKV) is an emerging orthoflavivirus causing serious neurologic disorders in neonates (congenital microcephaly) and adults (Guillain-Barré syndrome). Non-structural protein 5 (NS5), the largest and most conserved protein in the orthoflaviviruses, catalyses the synthesis and capping of new viral genomes. In addition to viral RNA replication in the cytoplasm, ZIKV NS5 is translocated into the nucleus to interfere with host antiviral responses. Here, we demonstrate that ZIKV NS5 co-immunoprecipitates with cellular UBA1. Immunofluorescence assays suggest that this interaction takes place primarily in the nucleus of an infected cell, although colocalization of both proteins is also detected in the cytosol. RNA interference-mediated depletion of UBA1 leads to reduced virus titres in the infected cells, while transient overexpression of UBA1 favours faster replication kinetics, with higher virus titres and protein levels detected. Moreover, UBA1-targeting drugs cause significant drops in virus infectivity. These results support a proviral role for UBA1 during ZIKV infection and encourage the potential use of inhibitors against this enzyme or its NS5-interacting epitopes as potential therapeutic targets.

Download full-text PDF

Source
http://dx.doi.org/10.1099/jgv.0.002063DOI Listing

Publication Analysis

Top Keywords

ubiquitin-like modifier-activating
8
modifier-activating enzyme
8
zika virus
8
infected cell
8
protein degradation
8
degradation pathways
8
zikv ns5
8
virus titres
8
protein
6
virus
5

Similar Publications

Ubiquitin-like modifier-activating enzyme 1 interacts with Zika virus NS5 and promotes viral replication in the infected cell.

J Gen Virol

January 2025

Unidad de Medicina Molecular, Instituto de Biomedicina de UCLM (IB-UCLM), Universidad de Castilla-La Mancha (UCLM), Albacete, Spain.

Translation errors, impaired folding or environmental stressors (e.g. infection) can all lead to an increase in the presence of misfolded proteins.

View Article and Find Full Text PDF

Aortic dissection (AD) is a life-threatening aortopathy with no specific pharmacological therapy. Ubiquitination, a highly orchestrated enzymatic cascade involving sequential E1-E2-E3 interactions, is suggested to contribute to the disease pathogenesis. However, the specific role of E1 enzymes in AD progression remains unknown.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined clinical differences among various antibody phenotypes in 293 patients with dermatomyositis (DM) from 2018 to 2023.
  • Key findings revealed that patients with anti-MDA5 antibodies were more likely to experience respiratory issues and fever, while those with anti-TIF1-γ antibodies had higher rates of malignancy and certain skin symptoms.
  • Prognostic factors influencing survival included age at onset, presence of fever, eosinophil levels, and complement 3 levels, with specific impacts identified through statistical analysis.
View Article and Find Full Text PDF

How cancer cells escape immune surveillance and resist immune checkpoint blockade (ICB) remains to be fully elucidated. By screening candidate genes frequently gained in cancer, we identified expression of ubiquitin-like modifier activating enzyme 1 (UBA1) as being the most negatively correlated with signatures related to effector CD8+ T-cells. High UBA1 expression was strongly predictive of treatment resistance and poor survival in ICB cohorts.

View Article and Find Full Text PDF
Article Synopsis
  • VEXAS syndrome is a newly identified disorder caused by mutations in the UBA1 gene, leading to serious symptoms like recurrent fevers, inflammation, and organ issues, including potential end-organ damage and death.
  • Treatment options are limited, but using the drug tocilizumab, which targets interleukin-6, has shown promise in managing the condition.
  • A case study of a 71-year-old male patient highlights the effectiveness of tocilizumab followed by siltuximab, with positive outcomes and no relapses reported for over a year.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!